Search Results
Found 434 results
510(k) Data Aggregation
(245 days)
The Atellica CH Diazo Total Bilirubin (D_TBil) assay is for in vitro diagnostic use in the quantitative determination of total bilirubin in human serum and plasma of adults and neonates using the Atellica CH Analyzer. Measurement of total bilirubin, an organic compound formed during the normal and abnormal destruction of red blood cells, is used in the diagnosis and treatment of liver, hemolytic, hematological, and metabolic disorders, including hepatitis and gallbladder block. A total bilirubin measurement in newborn infants is intended to aid in indicating the risk of bilirubin encephalopathy (kernicterus).
Atellica CH Diazo Total Bilirubin is a photometric test using 2,4-dichloroaniline (DCA). Direct bilirubin in presence of diazotized 2,4-dichloroaniline forms a red colored azocompound in acidic solution. A specific mixture of detergents enables the determination of the total bilirubin.
N/A
Ask a specific question about this device
(175 days)
The ATLAS™ Expandable Osteotomy Wedge System is an expandable osteotomy wedge fusion device used for internal bone fixation for bone fractures, fusions, or osteotomies in the foot and ankle.
The ATLAS™ Expandable Osteotomy Wedge System is intended for use with supplemental fixation for use in the foot or ankle.
The ATLAS™ Expandable Osteotomy Wedge System is not intended for use in the spine.
The ATLAS™ Expandable Osteotomy Wedge System is an expandable osteotomy wedge fusion device used for internal bone fixation for bone fractures, fusions, or osteotomies in the foot and ankle.
The ATLAS™ Expandable Osteotomy Wedge System consists of implants manufactured from Titanium-6 Aluminum-4 Vanadium ELI per ASTM F136. Expansion mechanism components are manufactured from Molybdenum-47.5 Rhenium Alloy (MoRe) per ASTM F3273. Instrumentation are manufactured from Stainless Steel per ASTM F899.
The ATLAS™ Expandable Osteotomy Wedge System implants are offered in multiple configurations and different sizes to accommodate various patient anatomical requirements. The implants (osteotomy wedges) will be provided sterile packed and are intended for single use only. The instruments will be provided non-sterile and will be steam sterilized by the end user.
N/A
Ask a specific question about this device
(466 days)
The Athelas Home is indicated for the quantitative determination of white blood cells (WBC) and Neutrophil percentages (NEUT%) in capillary whole blood from fingerstick for patient self-testing with results viewable by healthcare professionals, and in capillary or K2EDTA venous whole blood for multiple-patient use in point-of-care settings. For self-testing, the Athelas Home is intended to be used by a single person and should not be shared. The Athelas Home is only to be used with Athelas Test Strips. The Athelas Home is intended for adult patients (aged 21 and older) at risk of neutropenia. For self-testing patients with psychiatric conditions, clinical judgment should be exercised when deciding the end-user and based on the instructions for use (IFU), the treating physician should determine which patients are competent to perform the test by themselves. Results obtained with the Athelas Home should not be the sole basis for patient diagnosis, treatment, or management of leukopenia and neutropenia, and all results should be evaluated by a healthcare provider. Prescription Use Only.
The Athelas Home is identical to the Athelas Home (K200828) and Athelas One (K181288) in its technology, core software, the analytes measured, all components, and usage process.
The Athelas Home is an automated diagnostic device intended to perform tests on whole blood samples collected in K2EDTA or capillary finger stick samples collected directly into the Athelas test strip. Athelas Home returns quantitative WBC and Neut% metrics from the blood sample. The Athelas Home system is for In Vitro Diagnostic use and for prescription use only.
The Athelas Home is only to be used with Athelas Test Strips. The Athelas Home is indicated for use by patients and caregivers within home settings and at Point-of-Care settings with results viewable by health care professionals. The Athelas Home is indicated for adult populations only (aged 21 and older).
The Athelas Home is not indicated to completely replace a patient's monitoring regimen on reference lab systems. Prescribers should continue monitoring patients using traditional lab-based means as deemed necessary and possible.
The Athelas Home is not indicated to directly diagnose or assist in disease management. Rather, the Athelas Home should be used to quantify WBC and Neut% only, with all decision making owned by the health care professional as per standard of care.
The Athelas Home uses image processing and microfluidics in order to measure WBC and NEUT% values from whole blood in point-of-care and home settings. A drop of blood is placed on the Athelas test strip either directly from the finger or via pipette from K2EDTA whole blood tube. The device uses single-use, disposable test strips, ensuring there is no direct patient contact or contamination with the device itself.
The Athelas Home test strip stains and creates a monolayer of the blood sample within the chamber. The strip is inserted into the test strip slot of the Athelas Home device where a built-in camera captures images of the sample. The images are automatically transmitted to the cloud server where they are processed and analyzed by an image processing algorithm. The quantitative results of WBC, NEUT% results are based on the concentrations and types of cells present in the sample.
Here's a breakdown of the acceptance criteria and study information for the Athelas Home device, based on the provided FDA 510(k) clearance letter:
1. Acceptance Criteria and Reported Device Performance
| Acceptance Criteria | Reported Device Performance (WBC) | Reported Device Performance (Neut%) |
|---|---|---|
| WBC Precision: | ||
| - 7.5% CV above 2K/µL WBC | Within-run Precision/Reproducibility: 2.20 K/µL (5.87% CV), 3.75 K/µL (5.46% CV), 4.12 K/µL (5.09% CV), 5.11 K/µL (5.96% CV), 7.89 K/µL (4.82% CV), 10.01 K/µL (5.45% CV), 14.64 K/µL (4.69% CV), 17.52 K/µL (4.34% CV), 23.33 K/µL (5.81% CV). All met. | |
| - 0.25 K/µL SD below 2K/µL WBC | Not explicitly detailed for each sample below 2K/µL, but overall "All results met the predefined specifications (CV%) for precision." "Overall reproducibility levels were found to meet the acceptance criteria of 7.5% CV for WBC." (Implicitly including SD for lower range). Low-level QC (2.746 K/µL) showed a SD of 0.153 K/µL. | |
| WBC Bias/Error: | ||
| - ±7.5% error above 2K/µL WBC | Method Comparison: -2.31% Mean % Bias (1.1 - 23 K/µL range). Satisfied. | |
| - ±0.25 K/µL error below 2K/µL WBC | Not explicitly detailed for each sample below 2K/µL. | |
| Neutrophil % Precision: | ||
| - 5% SD OR 15% CV | Within-run Precision/Reproducibility: Not explicitly detailed for each sample, but overall "All results met the predefined specifications...for precision." (Implicitly including Neut%). | |
| Reproducibility (Overall Summary Table - Low): 2.680 SD (5.278% CV) Within-run. Total SD 3.443 (6.780% CV). Satisfied. | ||
| Reproducibility (Overall Summary Table - Medium): 3.015 SD (6.030% CV) Within-run. Total SD 3.344 (6.689% CV). Satisfied. | ||
| Reproducibility (Overall Summary Table - High): 2.967 SD (5.838% CV) Within-run. Total SD 3.316 (6.525% CV). Satisfied. | ||
| Neutrophil % Bias: | ||
| - ±10% bias or ±5% Neut% total error (whichever larger) | Method Comparison: 1.18% Mean % Bias (8 - 92.89% range). Satisfied. | |
| At-Home Precision (WBC) | At-Home Precision Repeatability: 5.4% CV (combined patient blood and QC material). Pass (Evaluation Criteria: 7.5% CV). | |
| At-Home Precision (Neut%) | At-Home Precision Repeatability: 1.2% SD (combined patient blood and QC material). Pass (Evaluation Criteria: 5% SD or 15% CV). | |
| Linearity (WBC) | R² = 0.997, Slope = 1.013, Intercept = 0.0449, CVr = 5.08% as per OLS regression. Demonstrated to be linear from lower limit to upper limit and within measured allowable max % diff for each interval. | |
| Flagging Accuracy | % Positive Agreement (Sensitivity): 90.91%. % Negative Agreement (Specificity): 96.71%. % Overall Agreement: 94.87%. Met the specification of >= 90%. | |
| Matrix Comparability (WBC - venous vs capillary) | WBC: Slope 1.026 (1.000, 1.055), Intercept -0.145 (-0.319, 0.018), Mean Bias 0.056 K/µL, Mean % Bias -0.588. Met all evaluation criteria. | |
| Matrix Comparability (Neut% - venous vs capillary) | Neut%: Slope 0.999 (0.938, 1.058), Intercept 0.457 (-2.502, 3.614), Mean Bias 0.162 Percentage Points, Mean % Bias -0.333. Met all evaluation criteria. | |
| At-Home Method Comparison (WBC - Athelas One vs Athelas Home) | WBC: Slope 1.0 (0.95, 1.03), Intercept 0 (-0.16, 0.31), Mean Bias 0, Mean % Bias 0.0. Met all evaluation criteria. | |
| At-Home Method Comparison (Neut% - Athelas One vs Athelas Home) | Neut%: Slope 1.0 (0.98, 1.09), Intercept -1.0 (-6.09, 0.0), Mean Bias -0.5, Mean % Bias 1.3. Met all evaluation criteria. | |
| At-Home Error Rate | Over 94% of tests run successfully with no errors. Errors that were found were resolved after running a single additional test-strip. | |
| At-Home Usability | Large majority of patients found the Athelas Home easy to use and had very little difficulty running the test end to end. (e.g., Lancet use: 32/32 Yes; Test-strip fill: 30/32 Yes; No errors (non-code): 31/32 Yes; App use: 32/32 Yes). | |
| Fill-Volume Testing | Robust to variable volumes of blood. Errors returned for 0µL. Accurate results within bias criteria for 1.4µL, 3.4µL, and 5.4µL fill volumes across various sample concentrations. | Robust to variable volumes of blood. Errors returned for 0µL. Accurate results within bias criteria for 1.4µL, 3.4µL, and 5.4µL fill volumes across various sample concentrations. |
| Device Tilt Testing | Not affected by tilted placement. No significant bias across tilt orientations and samples. All WBC criteria met. | Not affected by tilted placement. No significant bias across tilt orientations and samples. All Neut% criteria met. |
| Device Drop Testing | Robust to drop and vibration schedules. All 12 devices passed functional tests after testing, with no critical physical damage or functional defects, and WBC results remained within reference range. | Robust to drop and vibration schedules. All 12 devices passed functional tests after testing, with no critical physical damage or functional defects, and Neut% results remained within reference range. |
| Device/Test-Strip Temperature Testing | Both device and test-strip continued to meet performance specifications after exposure to extreme temperatures. All WBC bias criteria met. | Both device and test-strip continued to meet performance specifications after exposure to extreme temperatures. All Neut% bias criteria met. |
| Humidity Flex Testing (Test-Strips) | Test-strips continued to function within specifications after exposure to extreme humidity conditions. No evidence of condensation, fill-time within criteria (< 25 seconds), and no color change present for all 8 test strips across schedules. | |
| Vibration Testing | System successfully met evaluation criteria post vibration test. | |
| Cleaning and Disinfection | No change in performance or external materials after 10,000 cleaning and disinfection cycles using Caviwipe. |
2. Sample Sizes Used for the Test Set and Data Provenance
- Bench Testing (Within-run Precision):
- Sample Size: 9 whole blood samples. 10 replicates per sample, per operator, per test strip lot. Total of 90 tests per sample (90 tests x 9 samples = 810 tests).
- Data Provenance: Not specified, but generally from a laboratory setting.
- Bench Testing (Between-run Reproducibility):
- Sample Size: Three levels of ATH-check quality control material (Low, Normal, High). 240 readings per level (2 runs x 20 days x 2 replicates x 3 sites). Total of 720 readings across all levels.
- Data Provenance: Not specified, but implied to be from laboratory/controlled settings across three sites.
- At-Home Precision Study (Patient In-home Whole Blood):
- Sample Size: 24 patients, 2 replicates per patient. Total of 48 individual tests.
- Data Provenance: From at-home users in home environments in the US (implied by "at-home settings in the US" in subsequent sections and the study name).
- At-Home Precision Study (Patient In-home QC Material):
- Sample Size: 10 patients, 3 replicates per patient. Total of 30 individual tests.
- Data Provenance: From at-home users in home environments in the US.
- Linearity:
- Sample Size: 10 samples run in 4 replicates on 4 devices. Total of 160 tests.
- Data Provenance: Samples obtained by pooling "one low WBC concentration fresh whole blood sample one high WBC concentration sample." Generally laboratory prepared samples.
- Interfering Substances:
- Sample Size: Not explicitly stated how many individual samples were spiked and tested for each substance, but a list of 16 substances were tested.
- Data Provenance: Prepared whole blood samples, some naturally occurring, some spiked.
- Reference Intervals:
- Sample Size: 120 healthy donors.
- Data Provenance: Not specified, implied to be based on healthy donors.
- Limit of Blank (LoB):
- Sample Size: 120 total repeated measurements of blank samples.
- Limit of Detection (LoD):
- Sample Size: 2 test strip lots (60 strips each), 5 low-level samples, 2 replicates per sample. Total of 20 low-level tests for LoD calculation (across each lot, 5 samples x 2 replicates).
- Limit of Quantification (LoQ):
- Sample Size: 2 test-strip lots, 1 instrument, 3 days, 3 replicates per sample, 4 independent low-level whole blood samples. Total of 36 low-level tests (4 samples x 3 replicates x 3 days?) + more for the two lots.
- Data Provenance: Distinct whole blood samples acquired from patients in K2EDTA tubes, presumably from a laboratory or clinical setting. Diluted to target concentrations.
- Specimen Stability (Whole Blood):
- Sample Size: 9 different venous blood samples (low, normal, high WBC levels).
- Data Provenance: Venous blood samples.
- Specimen Stability (Test Strip):
- Sample Size: Two test strip lots compared over 26 months, 3 replicates, multiple QC lots. Three replicates per two lots of strips across 3 levels of control fluid run every 60 days.
- Method Comparison:
- Sample Size: 312 patient samples.
- Data Provenance: Taken at 3 point-of-care sites in the US.
- Flagging Comparison:
- Sample Size: 312 samples (same as Method Comparison).
- Data Provenance: Same as Method Comparison (3 point-of-care sites in the US).
- Matrix Comparison (Venous vs. Capillary):
- Sample Size: 59 patients.
- Data Provenance: Capillary finger-prick blood samples and K2EDTA venous whole blood samples from the same patients.
- At-Home Method Comparison:
- Sample Size: 165 samples.
- Data Provenance: Taken in at-home settings in the US.
- At-Home Error Analysis:
- Sample Size: 81 tests (derived from percentages: 76 successful, 3+2+1+1=7 errors, 76/0.94 = 80.85; 7/0.06 = 116.6; approximation derived from given percentages. The actual number is not precisely 81 based on the sum, but implies around this amount.)
- Data Provenance: At-home testing.
- At-Home Usability Analysis:
- Sample Size: 32 users.
- Data Provenance: At-home users during at-home visits.
- Fill-Volume Testing:
- Sample Size: 3 samples tested across 4 fill volumes (0µL, 1.4µL, 3.4µL, 5.4µL). Number of replicates not explicitly stated, but common for such studies.
- Data Provenance: K2EDTA whole blood samples for predicate comparison.
- Device Tilt Testing:
- Sample Size: 3 samples tested across 4 tilt conditions. Number of replicates not explicitly stated.
- Data Provenance: K2EDTA whole blood samples for predicate comparison.
- Device Drop Testing:
- Sample Size: 12 devices.
- Data Provenance: Device testing.
- Device and Test-Strip Temperature Testing:
- Sample Size: Device testing: 3 devices, 9 replicates each, across 3 environmental conditions. Test-strip testing: 3 test-strip lots, 9 replicates each, across 3 environmental conditions.
- Data Provenance: Device and test strips exposed to controlled environmental conditions.
- Vibration Testing:
- Sample Size: Not specified, but refers to "The system".
- Data Provenance: Third party ISTA certified test lab Quanta Testing.
- Humidity Flex Testing:
- Sample Size: 8 test-strips, subject to specified schedules.
- Data Provenance: Test-strips exposed to controlled humidity chambers at Quanta Laboratories.
3. Number of Experts Used to Establish Ground Truth and Qualifications
The document does not explicitly state the number or qualifications of experts used to establish ground truth.
However, it implicitly relies on:
- Predicate devices: The Sysmex XE-5000 and Athelas One are frequently used as the "ground truth" or reference method for comparison. These are legally marketed, validated automated hematology analyzers.
- Clinical Laboratory Standards Institute (CLSI) recommendations: The studies (precision, linearity, LoQ, stability) frequently refer to CLSI guidelines (e.g., CLSI EP05-A3, EP06-A, EP17-A2, EP25-A) as the basis for their methodologies and acceptance criteria, implying adherence to established best practices in laboratory medicine.
- Medical decision levels: The testing was conducted around "medical decision levels," which are established by clinical experts.
- Morphological flagging: This implies comparison against expert (e.g., pathologist, trained medical technologist) review of blood smears, though not directly stated.
Without explicit mention, it's not possible to state "X number of radiologists with Y years of experience," as the device is for hematology, not radiology.
4. Adjudication Method for the Test Set
The document does not explicitly describe an adjudication method for the test set (e.g., 2+1, 3+1, none).
- For method comparison studies, the predicate device (Sysmex XE-5000 or Athelas One) serves as the reference, which performs automated analysis. The "ground truth" is effectively the results from this established, high-accuracy device.
- For flagging comparison, the Sysmex XE-5000's flagging is used as the reference, which would typically be based on its internal algorithms and potentially validated against expert manual differential counts in its own clearance studies.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
No Multi-Reader Multi-Case (MRMC) comparative effectiveness study was mentioned. The studies focus on the device's analytical performance against predicate devices or its own established metrics, not on how human readers improve with or without AI assistance. The Athelas Home is an automated system providing quantitative results, not an AI-assisted diagnostic aid for human interpretation.
6. Standalone (Algorithm Only) Performance
Yes, the studies primarily describe standalone performance of the algorithm.
- The device captures images, transmits them to a cloud server, where they are "processed and analyzed by an image processing algorithm."
- The results for WBC and NEUT% are "based on the concentrations and types of cells present in the sample" as determined by this algorithm.
- All the performance metrics (precision, bias, linearity, LoD, LoQ, method comparison, flagging) describe the output of the device (i.e., the algorithm and hardware combined) compared to a reference method, without direct human-in-the-loop assistance for interpretation of individual results. Human healthcare professionals evaluate the overall results and provide diagnosis/treatment.
7. Type of Ground Truth Used
- Predicate device measurements: The primary ground truth for quantitative measurements (WBC, NEUT%) was the Sysmex XE-5000 analyzer (a widely accepted automated hematology analyzer) and the Athelas One (the previous generation predicate Athelas device).
- Quality Control (QC) material values: For precision and linearity studies, established values of QC materials (ATH-CHECK) were also used.
- Blank samples: For Limit of Blank.
- Diluted patient samples: For Limit of Quantification.
- Expert consensus/pathology (implied): For flagging comparison and verification of morphological flags, the reference Sysmex XE-5000's flagging implies an underlying ground truth (likely derived from expert manual differentials or pathology review during its own validation), which the Athelas One then compares to. This is not directly stated for Athelas Home validation, however.
- Pre-established reference intervals: For verifying reference intervals against Sysmex XE-5000.
- Outcomes data (No): Not mentioned as a ground truth.
8. Sample Size for the Training Set
The document does not specify the sample size for the training set. It focuses entirely on the validation/test set performance. It mentions that the "images are automatically transmitted to the cloud server where they are processed and analyzed by an image processing algorithm," implying a machine learning component, but provides no details on its development or training data.
9. How the Ground Truth for the Training Set Was Established
As the training set sample size is not specified, neither is the method for establishing its ground truth. However, given the nature of the device (automated cell counter), it would typically involve:
- Expert manual differential counts: Morphological classification and counting of various WBC types on blood smears by highly trained medical technologists or pathologists.
- Reference laboratory analyzer results: Pairing manual counts with results from established automated hematology analyzers for quantitative parameters.
- Annotated images: Images used for training would require meticulous annotation by experts to identify and classify different cell types.
Ask a specific question about this device
(262 days)
The Atellica® IM TSH3‑Ultra II (TSH3ULII) assay is for in vitro diagnostic use in the quantitative determination of thyroid-stimulating hormone (TSH, thyrotropin) in human serum and plasma (EDTA and lithium heparin) using the Atellica® IM Analyzer. Measurements of thyroid stimulating hormone produced by the anterior pituitary are used in the diagnosis of thyroid or pituitary disorders.
This assay is a third-generation assay that employs anti-FITC monoclonal antibody covalently bound to paramagnetic particles, an FITC-labeled anti-TSH capture mouse monoclonal antibody, and a tracer consisting of a proprietary acridinium ester and an anti‑TSH mouse monoclonal antibody conjugated to bovine serum albumin (BSA) for chemiluminescent detection.
N/A
Ask a specific question about this device
(222 days)
Atellica IM total PSA II (tPSAII) assay is for in vitro diagnostic use in the quantitative measurement of total prostate-specific antigen (PSA) in human serum and plasma (EDTA and lithium-heparin) using the Atellica IM Analyzer.
This assay is indicated as an aid in the detection of prostate cancer in conjunction with a digital rectal exam (DRE) in men aged 50 years and older. Prostate biopsy is required for diagnosis of prostate cancer. This assay is further indicated as an aid in the management (monitoring) of patients with prostate cancer.
The Atellica IM total PSA II (tPSAII) assay consists of:
tPSAII ReadyPack® primary reagent pack
- Lite Reagent (10.0 mL/reagent pack): Unlabeled monoclonal mouse anti-fPSA antibody (~250 ng/mL); monoclonal mouse anti-PSA antibody (~180 ng/mL) labeled with acridinium ester; buffer; bovine serum albumin (BSA); preservative.
- Solid Phase (20.0 mL/reagent pack): Monoclonal mouse anti-PSA antibody (~3.5 μg/mL) labeled with biotin and bound to streptavidin paramagnetic particles; buffer; BSA; bovine gamma globulin (BGG); sodium azide (< 0.1%); preservative.
- Storage: Unopened at 2–8°C (Until expiration date on product), Onboard (42 days).
tPSAII CAL (2.0 mL/vial): Purified PSA from human seminal fluid in buffer; BSA; NaN3 (< 0.1%).
- Storage: Unopened at 2–8°C (Until expiration date on product), Opened at 2–8°C (30 days), On the system at room temperature (8 hours).
The tPSAII assay will have two configurations: 100 tests kit and 500 tests kit (5 x 100T in the carton).
N/A
Ask a specific question about this device
(134 days)
Ask a specific question about this device
(217 days)
Atlantis Abutment & Atlantis Abutment Milling
The Atlantis Abutment and Atlantis Abutment Milling are intended for use with an endosseous implant to support a prosthetic device in a partially or completely edentulous patient. It is intended for use to support single and multiple tooth prosthesis, in the mandible or maxilla. The Atlantis Abutment screw is intended to secure the Atlantis Abutment to the endosseous implant.
Atlantis Crown Abutment
The Atlantis Crown Abutment is intended for use with an endosseous implant to function as a substructure that also serves as the final restoration, in a partially or completely edentulous patient. The Atlantis Abutment screw is intended to secure the Atlantis Crown Abutment to the endosseous implant.
Atlantis Conus Abutment
The Atlantis Conus Abutment is intended for use with an endosseous implant to support a prosthetic device in partially or completely edentulous patients. It is intended for use to support a removable multiple tooth prosthesis, in the mandible or maxilla. The prosthesis is an attachment-retained by friction fit to the abutment. The Atlantis Abutment screw is intended to secure the Atlantis Conus Abutment to the endosseous implant.
Atlantis Healing Abutment
The Atlantis Healing Abutment is intended for use with an endosseous implant for temporary use during soft tissue healing after one-stage or two-stage surgeries. The Atlantis Abutment screw is intended to secure the Atlantis Healing Abutment to the endosseous implant.
Implant Manufacturer: Institut Straumann
Implant System: Straumann BLX
Implant Diameter (in mm): 3.5, 3.75, 4.0, 4.5, 5.0, 5.5, 6.5
Abutment Platform Diameter (in mm): 2.69
Implant System: Neodent GM
Implant Diameter (in mm): 3.5, 3.75, 4.0, 4.3, 5.0, 6.0, 7.0
Abutment Platform Diameter (in mm): 3.0
The Atlantis® Abutments in Titanium are patient-specific dental abutments that are intended for attachment to dental implants in the treatment of partially or totally edentulous jaws for the purpose of restoring chewing function. The design of the Atlantis® Abutments in Titanium is derived from patient dental models and is completed by Dentsply Sirona using computer-assisted design (CAD) technology according to the clinician's prescription. The final CAD design of the Atlantis® Abutment in Titanium is fabricated using computer-assisted manufacturing (CAM) to produce a customized, patient-specific device. Design and fabrication of the Atlantis® Abutment in Titanium is completed in internal Dentsply Sirona manufacturing facilities.
Alternatively, the CAD design, according to the clinician's prescription, can be performed by a laboratory or clinician in an FDA cleared abutment design software (3Shape Abutment Designer Software, K151455) within the design envelope of the Atlantis® Abutments which is codified in the validated and locked design library of the cleared software. Fabrication of the Atlantis® Abutment is then completed in internal Dentsply Sirona manufacturing facilities.
The Atlantis® Abutment in Titanium serves as a connection of the prosthetic construction and the endosseous implant. The lower part of the abutment is designed to fit with the specific implant geometry it is compatible, and the upper part design is according to the patient's specific anatomy. The Atlantis® Abutment, including the Conus and Healing abutments further described below, are available in Titanium or Gold-shaded (titanium nitride layer applied using PVD (Physical Vapor Deposition)) Titanium. The Crown Abutment which is another Atlantis® Abutment in Titanium, is only available in Titanium.
The Atlantis® Abutment design envelope became the basis for the other more specific designs that make up the Atlantis® Abutments in Titanium. The Atlantis® Abutment is intended for use with an endosseous implant and for single tooth restoration.
The Atlantis® Crown Abutment in Titanium is also a custom fabricated abutment using the same internal CAD/CAM technology. The Atlantis® Crown Abutment in Titanium incorporates a design that is a combination of an abutment and an anatomically accurate crown to constitute the final finished device. It functions as a substructure that also serves as the final abutment, in a partially or completely edentulous patient.
The Atlantis® Conus Abutment supports a removable prosthesis (bridges and overdentures) which is retained by friction fit to the abutment. The abutment connects to the prosthesis via caps embedded in the prosthesis.
The Atlantis® Healing Abutment is used with the compatible implants for temporary use during soft tissue healing after one-stage and two-stage surgeries. It is designed based on the planned final Atlantis® Abutment or Atlantis® Crown Abutment, using the same emergence profile as those abutments to achieve an aesthetic outcome during the soft tissue healing phase.
The proposed Atlantis® Abutments in Titanium for Straumann BLX Implant are compatible with the Straumann BLX Implants. This implant system is available in diameters of 3.5, 3.75, 4.0, 4.5 5.0, 5.5 and 6.5 mm and in lengths of 8, 10, 12, 14, 16, and 18 mm all with identical mating geometry.
The proposed Atlantis® Abutments in Titanium for Neodent GM Implant are compatible with the Neodent GM Implants. This implant system is available in diameters of 3.5, 3.75, 4.0, 4.3, 5.0, 6.0, and 7.0 mm and in lengths of 7, 8, 9, 10, 11, 11.5, 13, 15, 16, 17 and 18 mm, all with identical mating geometry.
N/A
Ask a specific question about this device
(54 days)
ATTUNE™ Total Knee System
Candidates for total knee replacement include patients with a severely painful and/or severely disabled joint resulting from osteoarthritis, post-traumatic arthritis, rheumatoid arthritis, or a failed previous implant.
ATTUNE™ Revision Sleeve LPS™ Femoral Adaptors
The DePuy LPS System is intended for use in replacement of the mid-shaft portion of the femur, proximal, distal and/or total femur, and proximal tibia, especially in cases that require extensive resection and replacement. Specific diagnostic indications for use include:
- malignant tumors (e.g., osteosarcomas, chondrosarcomas, giant cell tumors, bone tumors) requiring extensive resection and replacement;
- patient conditions of noninflammatory degenerative joint disease (NIDJD), e.g. avascular necrosis, osteoarthritis, and inflammatory joint disease (IJD), e.g., rheumatoid arthritis, requiring extensive resection and replacement;
- revision cases for a failed previous prosthesis requiring extensive resection and replacement;
- severe trauma requiring extensive resection and replacement.
The LPS System is also intended for use in bone loss post-infection, where the surgeon has elected to excise the bone and replacement is required.
The S-ROM tibial tray and the non-porous coated straight and bowed stems are intended for cemented use only.
The porous-coated metaphyseal sleeves are intended for either cemented or cementless applications.
A Total Knee Prosthesis is composed of individually packaged femoral, tibial and patellar components designed to replace the natural articular surface of the knee joint. The femoral component is a metal implant without a porous coating. The tibial component consists of a metal tibial base without porous coating, and a locking polyethylene insert. Some metal components have modular stems, porous and non porous-coated sleeves and/or modular augments. The patella component is an all polyethylene design.
The ATTUNE™ Revision Sleeve LPS™ Femoral Adaptors are designed as a component in the replacement of the natural articular surface of the knee joint or of the mid-shaft portion of the femur, proximal, distal and/or total femur, and proximal tibia. The ATTUNE Revision Sleeve LPS Femoral Adaptors are to be used to connect an ATTUNE Revision Femoral Sleeve to LPS System Components.
N/A
Ask a specific question about this device
(89 days)
The Atlas Spine HiRISE™ Expandable Cervical Corpectomy System is indicated for vertebral body replacement in the cervical spine (C2-T1). The System is designed for use with autogenous and/or allogeneic bone graft comprised of cancellous and/or corticocancellous bone graft as an adjunct to fusion.
When used in the cervical spine (C2-T1), Atlas Spine HiRISE™ Expandable Cervical Corpectomy System spacers are intended for use in skeletally mature patients to replace a diseased or damaged vertebral body caused by tumor, fracture, or osteomyelitis, or for reconstruction following corpectomy performed to achieve decompression of the spinal cord and neural tissues in the cervical degenerative disorders. These spacers are intended to restore the integrity of the spinal column even in the absence of fusion for a limited time period in patients with advanced stage tumors involving the cervical spine in whom life expectancy is of insufficient duration to permit achievement of fusion, with bone graft used at the surgeon's discretion. The System is intended to be used with supplemental fixation that has been cleared by the FDA for use in the cervical spine.
Not Found
N/A
Ask a specific question about this device
(212 days)
Atalante X is intended to perform ambulatory functions and mobility exercises, hands‐free, in rehabilitation institutions under the supervision of a trained operator for the following populations:
- Individuals with hemiplegia due to cerebrovascular accident (CVA)
- Individuals with spinal cord injuries at levels C4 to L5 (SCI)
- Individuals with multiple sclerosis (MS)
The operator must complete a training program prior to use of the device.
Atalante X is intended to be used on adolescents of 18 years and older and adults, able to tolerate a stand‐up position.
The device is not intended for sports or stair climbing.
Atalante X is a completely self‐balancing walking system for people with mobility disabilities. It is a fully powered hip‐knee‐ankle lower body exoskeleton with 12 actuated degrees of freedom. Atalante X is self‐balancing and includes dynamic‐walking control. Dynamic‐walking allows the Atalante X to consume significantly less power and have a more natural gait.
N/A
Ask a specific question about this device
Page 1 of 44